BRAF and neoplasm: Conversely, KRAS (p = 2.67e−90), FBXW7 (p = 1.29e−14), BRAF (p = 9.32e−8), GNAS (p = 2.54e−29), and SMAD2 (p = 3.93e−5) mutated tumors were significantly more common in MSLN high expressing tumor samples versus MSLN low expressing tumor samples (Fig. 2A).